These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 36347432)

  • 1. The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives.
    Sun R; Xiang J; Zhou Q; Piao Y; Tang J; Shao S; Zhou Z; Bae YH; Shen Y
    Adv Drug Deliv Rev; 2022 Dec; 191():114614. PubMed ID: 36347432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcytosis-enabled active extravasation of tumor nanomedicine.
    Zhou Q; Li J; Xiang J; Shao S; Zhou Z; Tang J; Shen Y
    Adv Drug Deliv Rev; 2022 Oct; 189():114480. PubMed ID: 35952830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving accessibility of EPR-insensitive tumor phenotypes using EPR-adaptive strategies: Designing a new perspective in nanomedicine delivery.
    Dhaliwal A; Zheng G
    Theranostics; 2019; 9(26):8091-8108. PubMed ID: 31754383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next-Generation Chemotherapeutics and Photodynamic Therapy--Problems, Solutions, and Prospects.
    Maeda H; Tsukigawa K; Fang J
    Microcirculation; 2016 Apr; 23(3):173-82. PubMed ID: 26237291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors.
    Kim J; Cho H; Lim DK; Joo MK; Kim K
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines.
    Greish K
    J Drug Target; 2007; 15(7-8):457-64. PubMed ID: 17671892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms.
    Zi Y; Yang K; He J; Wu Z; Liu J; Zhang W
    Adv Drug Deliv Rev; 2022 Sep; 188():114449. PubMed ID: 35835353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
    Sun D; Zhou S; Gao W
    ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment.
    Park J; Choi Y; Chang H; Um W; Ryu JH; Kwon IC
    Theranostics; 2019; 9(26):8073-8090. PubMed ID: 31754382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An EPR-Independent extravasation Strategy: Deformable leukocytes as vehicles for improved solid tumor therapy.
    Wu H; Li W; Hao M; Wang Y; Xue L; Ju C; Zhang C
    Adv Drug Deliv Rev; 2022 Aug; 187():114380. PubMed ID: 35662610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity.
    Maeda H
    Adv Drug Deliv Rev; 2015 Aug; 91():3-6. PubMed ID: 25579058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors.
    Ojha T; Pathak V; Shi Y; Hennink WE; Moonen CTW; Storm G; Kiessling F; Lammers T
    Adv Drug Deliv Rev; 2017 Sep; 119():44-60. PubMed ID: 28697952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy.
    Zhou Q; Dong C; Fan W; Jiang H; Xiang J; Qiu N; Piao Y; Xie T; Luo Y; Li Z; Liu F; Shen Y
    Biomaterials; 2020 May; 240():119902. PubMed ID: 32105817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
    Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
    Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Destruction of tumor vasculature by vascular disrupting agents in overcoming the limitation of EPR effect.
    Liu Z; Zhang Y; Shen N; Sun J; Tang Z; Chen X
    Adv Drug Deliv Rev; 2022 Apr; 183():114138. PubMed ID: 35143895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human solid tumors and clinical relevance of the enhanced permeation and retention effect: a 'golden gate' for nanomedicine in preclinical studies?
    Gawali P; Saraswat A; Bhide S; Gupta S; Patel K
    Nanomedicine (Lond); 2023 Jan; 18(2):169-190. PubMed ID: 37042320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
    Danhier F
    J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers.
    Fang J; Islam W; Maeda H
    Adv Drug Deliv Rev; 2020; 157():142-160. PubMed ID: 32553783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor targeting via EPR: Strategies to enhance patient responses.
    Golombek SK; May JN; Theek B; Appold L; Drude N; Kiessling F; Lammers T
    Adv Drug Deliv Rev; 2018 May; 130():17-38. PubMed ID: 30009886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platinum-based combination nanomedicines for cancer therapy.
    Li Y; Lin W
    Curr Opin Chem Biol; 2023 Jun; 74():102290. PubMed ID: 36989943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.